Cingulate Inc.

Cingulate Inc. is a clinical-stage pharmaceutical company developing differentiated prescription therapies, with its lead program CTx-1301 aimed at ADHD. The company is focused on advancing its pipeline through clinical development, regulatory filing, and eventual commercialization via partnerships or outsourced sales infrastructure.

1.16

— Cingulate Inc.
	%
Lead drug candidate development	70% Clinical development, manufacturing, and regulatory work for CTx-1301 and related pipeline assets.
Pipeline expansion and in-licensing	15% Evaluation of new products, product candidates, and acquisitions to broaden the portfolio.
Commercialization partnerships	10% Potential licensing and fee-for-service commercialization support for approved products.
Grant-funded development programs	5% Externally funded clinical and manufacturing work, including CTx-2103 support.

Cingulate does not yet sell commercial products, so its near-term counterparties are primarily clinical research...

Pharmaceutical licensing partnersprimary
Companies that may license CTx-1301 in the U.S. or internationally to commercialize the asset.
Clinical development vendorsprimary
CROs, investigators, and manufacturers that provide trial execution, supply, and testing services.
Regulatory agenciesprimary
FDA and comparable authorities that review the NDA and determine approval timing.
Future ADHD prescribers and patientsemerging
Physicians and patients who would use the product if approved, driving eventual product demand.

Cingulate is headquartered in the United States and its current development, regulatory, and commercialization planning...

•United States is the core operating and regulatory market
•FDA approval timing is critical to U.S. commercialization
•Indegene services are tied to U.S. commercialization planning
•International licensing is a potential future expansion path
•No disclosed product revenue by country to date

Cingulate’s strategy is to complete development of CTx-1301, file the NDA, and secure a pharmaceutical partner or...

File the NDA for CTx-1301short-term

Regulatory submission is the key milestone needed to move the lead asset toward approval and value creation.

Secure a strategic pharmaceutical partnershipshort-term

A partner can provide commercialization reach and reduce the need for Cingulate to build costly sales infrastructure.

Fund pipeline and commercialization needsshort-term

The company needs additional capital to continue development and support launch activities if approval is obtained.

Broaden the product pipelinemedium-term

Adding assets through in-licensing or acquisition can diversify risk beyond a single lead program.

Cingulate is a pre-revenue clinical-stage company, so its business depends on successful trials, regulatory approval,...

critical

Going-concern and financing risk

The company has no product revenue and expects to need additional capital to fund operations and commercialization.

Scope: Cash runway into fourth quarter 2025 under current plan
Materiality: high

high

Clinical and regulatory failure risk

CTx-1301 and other candidates may not achieve successful trial outcomes or FDA approval.

Scope: Lead asset NDA timing and approval pathway
Materiality: high

high

Commercialization execution risk

The company may rely on partners or outsourced providers for marketing, sales, market access, and distribution.

Scope: Indegene MSA and future licensing arrangements
Materiality: high

medium

Manufacturing and supply chain risk

Clinical supply and commercial-scale manufacturing timing can affect trial progress and launch readiness.

Scope: CTx-1301 and CTx-2103 development
Materiality: medium

medium

Key personnel retention risk

A small development-stage company depends heavily on a limited management and scientific team.

Scope: Management and R&D execution
Materiality: medium

Research and development expense accruals

Affects operating loss comparability quarter to quarter

Going-concern assessment

Important for liquidity and financial statement interpretation

Grant accounting and contingent royalty obligation

Affects cash flow, liabilities, and future commercialization economics

Future collaboration and license revenue recognition

Could materially change reported revenue once commercialization begins

Cingulate Inc.

Going-concern and financing risk

Clinical and regulatory failure risk

Commercialization execution risk

Manufacturing and supply chain risk

Key personnel retention risk

Minerva Neurosciences, Inc.

ACTUATE THERAPEUTICS, INC.

Cyclerion Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

Neurogene Inc.

LB PHARMACEUTICALS INC